Compare Citius Pharmaceuticals Inc (CTXR) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KLA Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while KLA Corp. trades at $200.88 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 18848.8× Citius Pharmaceuticals Inc's market cap, and KLA Corp. pays a 0.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and KLA Corp. for 60 Days on average.
| CTXR | KLAC | |
|---|---|---|
Market Cap | $13.62M | $256.72B |
Volume | 132,438 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $1.82 | $301.71 |
52-Week Low | $0.48 | $98.28 |
Typical Hold Time | 16 Days | 60 Days |
Enterprise Value | $3.79M | $257.97B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical momentum indicated by bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, and maintains impressive profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57 billion backlog and positioning the company for continued growth in semiconductor equipment markets.
KLA presents a compelling investment case with analyst consensus price target of $223.88 representing 14% upside potential. The stock benefits from strong AI infrastructure spending and dominant market position in semiconductor inspection equipment. Key risks include competitive pressures from Applied Materials and ASML, valuation multiples above industry averages, and potential margin compression from increased R&D spending. Institutional ownership remains strong with recent acquisitions by Envestnet Portfolio Solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
